دورية أكاديمية
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.
| العنوان: | Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. |
|---|---|
| المؤلفون: | L. Annino, M. L. Vegna, A. Camera, G. Specchia, G. Visani, G. Fioritoni, F. Ferrara, A. Peta, S. Ciolli, W. Deplano, F. Fabbiano, S. Sica, F. Di Raimondo, N. Cascavilla, A. Tabilio, P. Leoni, M. Baccarani, B. Rotoli, S. Amadori, F. Mandelli, INVERNIZZI, ROSANGELA |
| المساهمون: | L., Annino, M. L., Vegna, A., Camera, G., Specchia, G., Visani, G., Fioritoni, F., Ferrara, A., Peta, S., Ciolli, W., Deplano, F., Fabbiano, S., Sica, F., Di Raimondo, N., Cascavilla, A., Tabilio, P., Leoni, Invernizzi, Rosangela, M., Baccarani, B., Rotoli, S., Amadori, F., Mandelli |
| سنة النشر: | 2002 |
| المجموعة: | IRIS UNIPV (Università degli studi di Pavia) |
| مصطلحات موضوعية: | Adult acute lymphoblastic leukemia, Chemotherapy, Survival |
| الوصف: | The GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN) pretreatment on complete remission (CR) achievement and length, the influence of the addition of cyclophosphamide (random I) to a conventional 4-drug induction on CR rate and duration, and whether an early post-CR intensification (random II) by an 8-drug consolidation could improve CR duration. Median follow-up of this study was 7.3 years. From January 1988 to April 1994, among 794 adult (> 12 but < 60 years) patients registered, 778 were eligible. Their median age was 27.5 years; 73\% had B-lineage acute lymphoblastic leukemia (ALL) and 22\% had T-lineage disease; 18\% showed associated myeloid markers; 47 of 216 analyzed patients (22\%) had Philadelphia chromosome-positive ALL. Response to PDN pretreatment was observed in 65\% of cases. CR was achieved in 627 patients (82\%). Resistant patients and induction death rates were 11\% and 7\%, respectively. Random II was applied to 388 patients with CR; 201 had maintenance alone and 187 had consolidation followed by maintenance. The relapse rate was 60\%; isolated central nervous system relapses were 8\% of all CRs and 13\% of all relapses. Median survival (overall survival [OS]), continuous complete remission (CCR), and disease-free survival (DFS) were 2.2, 2.4, and 2 years, respectively. PDN pretreatment response resulted the main independent factor influencing CR achievement, OS, CCR, and DFS; the addition of cyclophosphamide in induction significantly influenced CR achievement in a multivariate analysis. Neither induction intensification nor early consolidation appeared to influence CCR and DFS duration. For the first time PDN pretreatment response proved to be a powerful factor predicting disease outcome in adult ALL patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/11806988; info:eu-repo/semantics/altIdentifier/wos/WOS:000173527000021; volume:99; issue:3; firstpage:863; lastpage:871; numberofpages:8; journal:BLOOD; http://hdl.handle.net/11571/564248Test |
| DOI: | 10.1182/blood.V99.3.863 |
| الإتاحة: | https://doi.org/10.1182/blood.V99.3.863Test http://hdl.handle.net/11571/564248Test |
| رقم الانضمام: | edsbas.4874E9D9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/blood.V99.3.863 |
|---|